Remember: First Right of Refusal - UC, Crohn’
Post# of 72446
(Total Views: 819)
Posted On: 01/21/2020 2:24:54 AM
Remember:
First Right of Refusal - UC, Crohn’s https://www.investopedia.com/terms/r/rightoffirstrefusal.asp
First Right to Negotiate- other Gastro Indications
https://www.quora.com/What-is-the-right-of-first-negotiation
“We are thrilled to forge this partnership with Innovation Pharmaceuticals,” said Pier Vincenzo Colli, Chief Executive Officer at Alfasigma. “The Phase 2 Brilacidin clinical study results in UP/UPS look promising and reflective of Brilacidin’s unique drug properties and treatment potential. Alfasigma plans to dedicate considerable internal resources, including formulation and IP expertise, and to make a substantial investment to advance Brilacidin, with the objective to offer patients a safe and effective new treatment option in the management of UP/UPS. We will also closely follow Innovation’s progress in developing oral Brilacidin, as we remain highly interested in novel oral IBD treatments. This agreement is a further step in strengthening our pipeline.”
I’m starting to think the B-UP/UPS deal, although small, was more of a handshake agreement between IPIX and AlphaSigma to start an early relationship that can blossom to something very big.
Read the whole licensing PR. AlphaSigma has first right of refusal for B-UC and Crohn’s and First right of negotiation on other gastro indications.
This makes me believe IPIX has terms in place, once and if, oral formulation works. We will know soon. Such is the case, I feel AlphaSigma may provide the funds to wrap up B-UC and Crohn’s which will enable IPIX to start Phase 3 or B-OM and then AS may have first rights of negotiations to that and other gastrointestinal indications.
AS may very well see this as a major partnership to the future sale of all indications to a large pharma. They get in early, help with their expertise and money and then reap the large rewards the future may bring.
Good stuff
First Right of Refusal - UC, Crohn’s https://www.investopedia.com/terms/r/rightoffirstrefusal.asp
First Right to Negotiate- other Gastro Indications
https://www.quora.com/What-is-the-right-of-first-negotiation
“We are thrilled to forge this partnership with Innovation Pharmaceuticals,” said Pier Vincenzo Colli, Chief Executive Officer at Alfasigma. “The Phase 2 Brilacidin clinical study results in UP/UPS look promising and reflective of Brilacidin’s unique drug properties and treatment potential. Alfasigma plans to dedicate considerable internal resources, including formulation and IP expertise, and to make a substantial investment to advance Brilacidin, with the objective to offer patients a safe and effective new treatment option in the management of UP/UPS. We will also closely follow Innovation’s progress in developing oral Brilacidin, as we remain highly interested in novel oral IBD treatments. This agreement is a further step in strengthening our pipeline.”
I’m starting to think the B-UP/UPS deal, although small, was more of a handshake agreement between IPIX and AlphaSigma to start an early relationship that can blossom to something very big.
Read the whole licensing PR. AlphaSigma has first right of refusal for B-UC and Crohn’s and First right of negotiation on other gastro indications.
This makes me believe IPIX has terms in place, once and if, oral formulation works. We will know soon. Such is the case, I feel AlphaSigma may provide the funds to wrap up B-UC and Crohn’s which will enable IPIX to start Phase 3 or B-OM and then AS may have first rights of negotiations to that and other gastrointestinal indications.
AS may very well see this as a major partnership to the future sale of all indications to a large pharma. They get in early, help with their expertise and money and then reap the large rewards the future may bring.
Good stuff
(7)
(2)